



CODEN [USA]: IAJ PBB

ISSN: 2349-7750

**INDO AMERICAN JOURNAL OF  
PHARMACEUTICAL SCIENCES**<http://doi.org/10.5281/zenodo.3229325>Available online at: <http://www.iajps.com>

Review Article

**PREVALENCE OF CARDIOVASCULAR DISEASE IN TYPE 2  
DIABETES- SYSTEMATIC LITERATURE REVIEW**<sup>1</sup>Dr Muhammad Ammaar Aslam, <sup>2</sup>Dr Ezzah Sajjad, <sup>3</sup>Dr Sadia Mushtaq<sup>1</sup>MO, BHU Bansrian, Kharian, Gujrat., <sup>2</sup>WMO, Shalamar Hospital, Lahore., <sup>3</sup>WMO, BHU  
59/MB, Khushab.

Article Received: March 2019

Accepted: April 2019

Published: May 2019

**Abstract:**

The international federation state that, 415 million people have diabetes, in which 91% have type 2 diabetes (T2DM). The overall world's population suffering from type 2 diabetes is 8.8% that too would rise to 642 million by 2040. Prevalence of type 2 diabetes mellitus has been increasing quickly with the passage of time. A study conducted by Abraham et al report that the incidence of the diabetes is 83.3% and higher in males than females. Cardiovascular disease is one of the major cause of death and causing disability among people suffering from diabetes. Adults who have diabetes have more prevalence of CVD as compared to adults without diabetes. And the risk of developing CVD increases continuously with rising fasting plasma glucose level. T2DM decreases the life expectancy by 10 years and one of the leading causes to death is CVD. Moreover, people with T2DM are more prone to develop CVD than no diabetic people. A study conducted to calculate the death rates due to cardiovascular disease over 7 year period in patient with and without type 2 diabetes.

CVD is one of the major cause of death in T2DM with coronary artery disease having the high prevalence.

**Corresponding author:****Dr. Muhammad Ammaar Aslam,**  
MO, BHU Bansrian, Kharian, Gujrat.

QR code



Please cite this article in press Muhammad Ammaar Aslam et al., *Prevalence of Cardiovascular Disease in Type 2 Diabetes- Systematic Literature Review.*, Indo Am. J. P. Sci, 2019; 06(05).

## INTRODUCTION:

The international federation state that, 415 million people have diabetes, in which 91% have type 2 diabetes (T2DM). The overall world's population suffering from type 2 diabetes is 8.8% that too would rise to 642 million by 2040 [1]. Prevalence of type 2 diabetes mellitus has been increasing quickly with the passage of time. A study conducted by Abraham et al report that the incidence of the diabetes is 83.3% and higher in males than females [2]. Cardiovascular disease is one of the major cause of death and causing disability among people suffering from diabetes [3]. Adults who have diabetes have more prevalence of CVD as compared to adults without diabetes [4]. And the risk of developing CVD increases continuously with rising fasting plasma glucose level [5]. T2DM decreases the life expectancy by 10 years and one of the leading causes to death is CVD. Moreover people with T2DM are more prone to develop CVD than no diabetic people. A study conducted to calculate the death rates due to cardiovascular disease over 7 year period in patient with and without type 2 diabetes.

People who had T2DM, the death rates were 15.4% to those who previously had no history of MI and 42.0% in patients having history of MI where as in patients who had no diabetes, the death rate were 2.1% and 15.9% respectively [6]. Literatures showed that the prevalence of T2DM is increasing along with the risk of CVD. The risks of having CVD in 1952-1974 were 5.4% whereas in 1975 the risks were increased to 8.7% [7].

Another longitudinal study conducted on 881 patients with T2DM over 10 years, conclude that ratio due to CVD constantly increasing each year [8] the clinical burden that CVD complications have on T2DM, the focus on the joint management has been increased. Plasma glucose level control is the main management in T2DM to protect the micro vascular complications and CVD [9] [10]. its role has not been yet cleared in T2DM. [11][12][13]. to prevent micro vascular complications other risk factors must be under consideration. There must be reduction in glucose level, smoking cessation, diet, exercise, blood pressure, and plasma lipid level. There are so many treatment guidelines present to prevent the onset of CVD [14]. There are several treatment to reduce CVD in non-diabetic people specially to prevent major events such as non-fatal MO, stroke etc[15] [16]

Following these regulatory requirements, several cardiovascular outcomes trials (CVOT) have been completed, which demonstrate that certain anti-diabetic treatments are associated with a lower risk of

CVD [17-20].

CVD includes coronary artery disease (CAD), cerebrovascular disease (CBV), and peripheral vascular disease, the focus of this review was on CVD outcomes that are relevant to major cardiovascular events. Therefore, the review specifically focused on the prevalence of CAD and CBV. CAD has many synonyms, including ischemic heart disease, coronary heart disease (CHD), atherosclerotic heart disease, and atherosclerotic CVD. Conditions within this category are stable angina pectoris, unstable angina pectoris, MI (also known as heart attack), and sudden cardiac death (SCD).

## METHODS:

This study was based on systematic review. 57 articles were reviewed. All the participants' age more than 18 having diabetes were included in this study. Prevalence rates were compared between male and female and between obese and no-obese patient. All the participants who previously had peripheral artery disease (PAD), rheumatic heart disease, cardiac dysrhythmias (e.g., atrial or ventricular fibrillation), or requirement for surgery such as coronary artery bypass grafting (CABG)/coronary revascularization were excluded.

### **Obese versus non obese and males versus females:**

About half of the patients included in this study had obesity. The most commonly used definition of obesity was a BMI  $\geq 30$  kg/m<sup>2</sup>. Literature reported that prevalence rates of CVD according to obesity, and found a positive relationship between obesity and increased prevalence rates of CVD. A study conducted by Bhatti et al found a positive correlation between obesity and CAD (P=0.021). [21][22][23]

Tamba et al. reported positive correlations between obesity and both CAD and stroke [24]. Boonman-de Winter et al quantified the relationship between BMI and heart failure. The prevalence rate of heart failure was 38.7% (95% CI 31.2–46.1%) in patients with a BMI  $\geq 30$  kg/m<sup>2</sup> and 23.4% (95% CI 19.4–27.5%) in those with a BMI  $< 30$  kg/m<sup>2</sup>, which represents a 65% increase due to obesity [25]

Studies explored the relationship between increasing BMI and risk of CVD. According to Wentworth et al, for CAD in both males and females, the prevalence rate of CAD increased with each successive increase in BMI, with a five-fold increase between the lowest and highest categories [40 kg/m<sup>2</sup> (severe obesity) [26]

The difference was that prevalence rates in males were about double those for females in every BMI category. For the outcome stroke/transient ischemic attack (TIA) in males, only the highest category (BMI>40) had elevated prevalence rates, which were about double those for the lowest category (BMI For females, prevalence rates of stroke/TIA increased in those who were overweight and had mild or moderate obesity but decreased for those with severe obesity. Finally, Glogner et al. had quite different results. They reported a steady increase in prevalence rates of MI from 6.86% in those with a BMI category of obesity. The highest category (BMI $\geq$ 40) had a prevalence rate of 5.01%, which was 27% lower than those in the lowest category (BMI  $\geq$ 40 ) had a prevalence rate of 5.01%, which was 27% lower than those in the lowest category Thus, patterns vary quite widely, and studies often examined different outcomes [27][28]

### DISCUSSION:

The overall estimated result of prevalence of CVD in T2DM was 32.2%. One of the most common type of CVD was coronary artery disease and rarest was stroke 7.6%. Males were more prone to prevalent diseases than females. CAD was the leading factor of death in T2DM. Together with CVD age and obesity are major risk factors.

#### Age as a risk factor

Age is a well-defined risk factor for CVD. Some studies support this idea whereas some might not. Alonso-Moran state that the risk of having MI, stroke, heart failure increased with the increase in 5 year category as compared with age group 35-39 used as reference [29]. Another study similarly report that the prevalence of heart failure increase with the increase of age [30]. Studies have reported that younger patients have less prevalence rates than older patients but they gave not given any age category to relate [31]. Whereas some studies have reported that there is no relation between age categories [32].

#### Obesity:

Obesity is an independent risk factor for CVD and strongly linked with coronary artery disease, atherosclerosis, and cardiac failure [33]. The prevalence of T2DM has been seen in overweight and obese patients; moreover they are more prone to develop cardiovascular diseases [34]. Obesity is defined according to WHO, adult having BMI 30kg/m<sup>2</sup> as obese. Therefore BMI measure is to warn people about their risk of having obese which is associated with so many risk factors [35]

Seven studies investigated the relationship of obesity

and CVD risk. Five of them showed the direct relation between obesity and and high prevalence of CVD [36].

One of these studies used lower BMI cut-of points to account for Asian populations in accordance with WHO recommendations on BMI for Asian populations and evaluated abdominal adiposity with waist circumference measurements to determine the prevalence of obesity [37]. Overall, the studies found a positive relationship between increasing BMI and CVD; except in one study, where women with severe obesity had a reduced prevalence of stroke [38] While the authors do not explain the reduced prevalence of stroke/ TIA, it may be explained by differences in vascular risk markers in men, such as pre-existing ischemic heart disease, age, and smoking [40]. Furthermore, the presence of gonadal steroids, most notably estrogen, may lend a protective effect against stroke/TIA in women and it has been shown that adiposity is associated with increased levels of estrogen. Although obesity is identified as a risk factor for CVD, it is associated with a paradox in that mortality is lower in patients who are overweight or obese than in those whose BMI is normal or underweight [41]. Lee et al. reported that obesity provided a survival benefit to patients with heart failure who did not have comorbid diabetes, but not in patients who did have concomitant diabetes. In contrast, a group led by Abi Khalil examined a cohort of 2492 T2DM patients in seven countries in the Middle East, Gulf region, with acute heart failure [42]

### CONCLUSION:

CVD is one of the major cause of death in T2DM with coronary artery disease having the high prevalence.

### REFERENCE:

1. International Diabetes Federation. idf diabetes atlas. 7th ed. Brussels: International Diabetes Federation; 2015.
2. Abraham TM, Pencina KM, Pencina MJ, Fox CS. Trends in diabetes incidence: the Framingham heart study. *Diab Care*. 2015;38:482–7
3. International Diabetes Federation. Diabetes and cardiovascular disease. Brussels: International Diabetes Federation; 2016. p. 1–144
4. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Angelantonio D, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. *emerging risk factors collaboration*. *Lancet*.

- 2010;375:2215–22.
5. Singh GM, Danaei G, Farzadfar F, Stevens GA, Woodward M, Wormser D, Kaptoge S, Whitlock G, Qiao Q, Lewington S. The age-specific quantitative effects of metabolic risk factors on cardiovascular diseases and diabetes: a pooled analysis. *PLoS ONE*. 2013;8:e65174.
  6. Hafner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. *N Engl J Med*. 1998;339:229–34.
  7. Fox CS, Pencina MJ, Wilson PW, Paynter NP, Vasani RS, D'Agostino RB. Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham heart study. *Diab Care*. 2008;31:1582–4.
  8. Van Hateren KJ, Landman GW, Kleefstra N, Logtenberg SJ, Groenier KH, Kamper AM, Houweling ST, Bilo HJ. The lipid profile and mortality risk in elderly type 2 diabetic patients: a 10-year follow-up study (ZODIAC-13). *PLoS ONE*. 2009;4:e8464.
  9. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med*. 1993;329:977–86.
  10. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. *N Engl J Med*. 2005;353:2643–53.
  11. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med*. 2008;358:2560–72.
  12. UK Prospective Diabetes Study. (UKPDS) Group: intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK prospective diabetes study (UKPDS) group. *Lancet*. 1998;352:837–53.
  13. Action to Control Cardiovascular Risk in Diabetes Study. Group: effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med*. 2008;358:2545–59.
  14. Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, Deaton C, Escaned J, Hammes H-P, Huikuri H. ESC guidelines on diabetes, prediabetes, and cardiovascular diseases developed in collaboration with the EASD-summary. *Diab Vasc Dis Res*. 2014;11:133–73.
  15. Schnell O, Rydén L, Standl E, Ceriello A. Updates on cardiovascular outcome trials in diabetes. *Cardiovasc Diabetol*. 2017;16:128.
  16. Food and Drug Administration: Guidance for industry: diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. US Department of Health and Human Services. 2008.
  17. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *N Engl J Med*. 2016;375:1834–44.
  18. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS. Liraglutide and cardiovascular outcomes in type 2 diabetes. *N Engl J Med*. 2016;2016:311–22.
  19. Sanon VP, Patel S, Sanon S, Rodriguez R, Pham SV, Chilton R. Differential cardiovascular profiles of sodium-glucose cotransporter 2 inhibitors: critical evaluation of empagliflozin. *Ther Clin Risk Manag*. 2017;13:603.
  20. Trujillo JM, Nufer WA. Impact of sodium-glucose cotransporter 2 inhibitors on nonglycemic outcomes in patients with type 2 diabetes. *Pharmacotherapy*. 2017;37:481–91.
  21. Bhatti GK, Bhadada SK, Vijayvergiya R, Mastana SS, Bhatti JS. Metabolic syndrome and risk of major coronary events among the urban diabetic patients: North Indian Diabetes and cardiovascular disease study—NID-CVD-2. *J Diab Complications*. 2016;30:72–8.
  22. Tamba SM, Ewane ME, Bonny A, Muisi CN, Nana E, Ellong A, Mvogo CE, Mandengue SH. Micro and macrovascular complications of diabetes mellitus in Cameroon: risk factors and effect of diabetic check-up—a monocentric observational study. *Pan African Med J*. 2013;15:141.
  23. Boonman-de Winter LJ, Rutten FH, Cramer MJ, Landman MJ, Liem AH, Rutten GE, Hoes AW. High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes. *Diabetologia*. 2012;55:2154–62.
  24. Wentworth JM, Furlan S, Colman PG. Body mass index correlates with ischemic heart disease and albuminuria in long-standing type 2 diabetes. *Diab Res Clin Pract*. 2012;97:57–62.
  25. Glogner S, Rosengren A, Olsson M, Gudbjörnsdóttir S, Svensson AM, Lind M. The association between BMI and hospitalization for heart failure in 83,021 persons with Type 2



- diabetes: a population-based study from the Swedish National Diabetes Registry. *Diab Med.* 2014;31:586–94.
26. Simmons RK, Griffin SJ, Lauritzen T, Sandbæk A. Effect of screening for type 2 diabetes on risk of cardiovascular disease and mortality: a controlled trial among 139,075 individuals diagnosed with diabetes in Denmark between 2001 and 2009. *Diabetologia.* 2017;60:2192–9.
  27. World Health Organization. Global status report on noncommunicable diseases. Geneva: World Health Organization; 2014. p. 1–302
  28. Nair M, Prabhakaran D. Why do South Asians have high risk for CAD? *Global Heart.* 2012;7:307–14.
  29. Alonso-Moran E, Orueta JF, Fraile Esteban JI, Arteagoitia Axpe JM, Marques Gonzalez ML, Toro Polanco N, Ezkurra Loiola P, Gaztambide S, Nuno-Solinis R. The prevalence of diabetes-related complications and multimorbidity in the population with type 2 diabetes mellitus in the Basque Country. *BMC Public Health.* 2014;14:1059.
  30. Boonman-de Winter LJ, Rutten FH, Cramer MJ, Landman MJ, Liem AH, Rutten GE, Hoes AW. High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes. *Diabetologia.* 2012;55:2154–62
  31. Song S, Hardisty C. Early onset type 2 diabetes mellitus: a harbinger for complications in later years—clinical observation from a secondary care cohort. *QJM.* 2009;102:799–806.
  32. Menghua Z. GW25-e1447 clinical significance of multislice coronary CT angiography in asymptomatic patients with type 2 diabetes mellitus. *J Am Coll Cardiol.* 2014;64:C227
  33. Engeland A, Bjorge T, Sogaard AJ, Tverdal A. Body mass index in adolescence in relation to total mortality: 32-year follow-up of 227,000 Norwegian boys and girls. *Am J Epidemiol.* 2003;157:517–23.
  34. Masmiqel L, Leiter L, Vidal J, Bain S, Petrie J, Franek E, Raz I, Comlekci A, Jacob S. Gaal Lv: LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial. *Cardiovasc Diabetol.* 2016;15:29
  35. World Health Organization. Obesity and Overweight. Factsheet No 311. Geneva: World Health Organization; 2017
  36. World Health Organization Expert Consultation. Appropriate body mass index for Asian populations and its implications for policy and intervention strategies. *Lancet.* 2004;363:157.
  37. Koellhofer EC, McCullough LD. The effects of estrogen in ischemic stroke. *Transl Stroke Res.* 2013;4:390–401.
  38. Meseguer A, Puche C, Cabero A. Sex steroid biosynthesis in white adipose tissue. *Horm Metab Res.* 2002;34:731–6
  39. Hartrumpf M, Kuehnel RU, Albes JM. The obesity paradox is still there: a risk analysis of over 15,000 cardio-surgical patients based on body mass index. *Interact Cardiovasc Thorac Surg.* 2017;25:18–24.
  40. Lee KS, Moser DK, Lennie TA, Pelter MM, Nesbitt T, Southard JA, Dracup K. Obesity paradox: comparison of heart failure patients with and without comorbid diabetes. *Am J Crit Care.* 2017;26:140–8.
  41. Abi Khalil C, Sulaiman K, Singh R, Jayyousi A, Asaad N, AlHabib KF, Alsheikh-Ali A, Al-Jarallah M, Bulbanat B, Al Mahmeed W, et al. BMI is inversely correlated to the risk of mortality in patients with type 2 diabetes hospitalized for acute heart failure: findings from the Gulf aCute heArt failuRE (Gulf-CARE) registry. *Int J Cardiol.* 2017;5273(0116):34386–8
  42. Straka RJ, Liu LZ, Girase PS, DeLorenzo A, Chapman RH. Incremental cardiovascular costs and resource use associated with diabetes: an assessment of 29,863 patients in the US managed-care setting. *Cardio-vasc Diabetol.* 2009;8:53.
  69. Senthil AN, Ravishankar G.